Active Ingredient(s): Peginesatide
FDA Approved: * March 27, 2012
Pharm Company: * AFFYMAX INC
Category: Anemia

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Omontys Overview

Peginesatide[2] (INN/USAN, trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.[3][4] On February 23, 2013, Affymax and Takeda issued a press release indicating that they were recalling all batches of pegi...

Read more Omontys Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Omontys Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 1mg/0.5ml, 2mg/0.5ml, 3mg/0.5ml, 4mg/0.5ml, 5mg/0.5ml, 6mg/0.5ml
  • Solution: 10mg/ml (10mg/ml), 1mg/0.5ml (1mg/0.5ml), 20mg/2ml (10mg/ml), 2mg/0.5ml (2mg/0.5ml), 3mg/0.5ml (3mg/0.5ml), 4mg/0.5ml (4mg/0.5ml), 5mg/0.5ml (5mg/0.5ml), 6mg/0.5ml (6mg/0.5ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Peginesatide or a similar ingredient: (1 result)